Clinical trial · Observational
Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow Up
NCT01098552CI-TRIAL-00008877completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is being done to collect regular and routine follow-up information related to the outcome of treatment for prostate cancer. This study is also being done to relate treatment outcome to measurement of substances in the blood such as prostate-specific antigen (PSA) and other markers. Also environmental and genetic factors that might be responsible for prostate cancer are being investigated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (6)
- label
- High-risk radical prostatectomy patients
- label
- Primary external beam radiotherapy patients
- label
- Primary prostate brachytherapy patients
- label
- Hormone refractory prostate cancer patients
- label
- Active Surveillance
- label
- Prostate biopsy patients
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Informed consent explained and signed prior to any study related procedures. 2. Age ≥18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or better, or Karnofsky performance of 60% or better. 4. Histologically confirmed adenocarcinoma of the prostate within 10 years of study entry. 5. Willingness to return to Mayo Clinic Rochester for follow-up or participate in mail-in PSA processing. 6. Must be disease-free from a previous diagnosis of cancer for a period of time = 5 years excluding cutaneous malignancies of squamous cell or basal cell carcinoma. Exclusion Criteria: 1. Life expectancy \< 5 years. 2. Inability to return to Mayo Rochester for follow-up appointments, sera, and urine collection per protocol. 3. Previous or a concurrent diagnosis of cancers other than basal cell or invasive squamous cell carcinoma of skin within the past 5 years.
References
Publications (0)
Data not yet available
No reference posted for this study.